On the contrary, Ma et al. demonstrated that in their lncRNA signature model, high HHLA2 expression corresponded to a low risk and longer overall survival for patients with CRC, while low HHLA2 levels were observed in the high-risk patients. The gene discussed is HHLA2; the disease is colorectal carcinoma.